Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients

REFERENCES

• Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatients Study Investigators. N Engl J Med. 1998; 338:853–860.
   PubMed Web of Science ®Google Scholar
• Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251–265.
   PubMed Web of Science ®Google Scholar
• Gallant J. Protease inhibitor boosting in the treatment-experienced patient. AIDS Rev. 2004;6:226–233.
   PubMed Web of Science ®Google Scholar
• Scott J. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-expe-rienced patients. Am J Health Syst Pharm. 2005;62:809–815.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, et al. Clinical progres-sion and virological failure on highly active antiretroviral therapy in HIV-1 patient: a prospective cohort study. Swiss HIV cohort study. Lancet. 1999;353:863–868.
   Google Scholar
• Clavel F, Hance A. HIV drug resistance. N Engl J Med. 2004;350:1023–1035.
   PubMed Web of Science ®Google Scholar
• Shafer R. Genotypic testing for HIV-1 drug resistance. Clin Microbiol Rev. 2002;15:247–277.
   PubMed Web of Science ®Google Scholar
• Hertogs K, Bloor S, Kemp S, et al. Phenotypic and geno-typic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 2002;14:1203–1210.
   Web of Science ®Google Scholar
• Paredes R, Puig T, Amo A, et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibi-tor-experienced patients and predictors of virologic re-sponse. J Acquir Immune Defic Syndr. 1999;22:132–138.
   PubMed Web of Science ®Google Scholar
• Johnson V, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. HIV Topics Med. 2005;13:51–57.
   PubMedGoogle Scholar
• Dragsted U, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected patients: the MaxCmin1 trial. J Infect Dis. 2003;188:635–642.
   PubMed Web of Science ®Google Scholar
• Dragsted U, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10:735–743.
   PubMed Web of Science ®Google Scholar
• Acosta E, Wu H, Hammer S, et al. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-in-fected individuals. J Acquir Immune Defic Syndr. 2004;37: 1358–1366.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in pa-tients experiencing multiple virological failures. AIDS. 2005;19:153–162.
   PubMed Web of Science ®Google Scholar
• Prado J, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir-cross-resistance and reduced rep-lication capacity. AIDS. 2002;16:1009–1017.
   PubMed Web of Science ®Google Scholar
• Parkin N, Chappey C, Petropoulos C. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS. 2003;17: 955–961.
   PubMed Web of Science ®Google Scholar
• Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection: a randomized non-inferiority trial. Lancet. 2006;368:476–482.
   PubMed Web of Science ®Google Scholar
• Barrios A, Rendon A, Gallego 0, et al. Predictors of viro-logical response to atazanavir in protease inhibitor-experi-enced patients. HIV Clin Trials. 2004;5:201–205.
   Google Scholar
• Haubrich R, Little S, Currier J, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virological and immunological response. AIDS. 1999;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Gallego O, de Mendoza C, Corral A, Barrios A, Soriano V. Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitor-experienced patients: implications for tipranavir use. AIDS Patient Care SMs 2005;19: 67–69.
   PubMed Web of Science ®Google Scholar
• Race E, Dam E, Obry V, Paulous S, Cleve! F. Analysis of HIV cross-resistance to PI using a rapid single-cycle re-combinant virus assay for patients failing on combination therapies. AIDS. 1999;13:2061–2068.
   Google Scholar
• Schapiro J, Winters M, Lawrence J, Merigan T. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. 1999;13:359–365.
   PubMed Web of Science ®Google Scholar
• Marcelin A, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in HIV type 1 protease inhibitor-expe-rienced patients. Antimicrob Agents Chemother. 2003;47: 594–600.
   PubMed Web of Science ®Google Scholar
• Marcelin A, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in HIV type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2004;48:4687–4692.
   PubMed Web of Science ®Google Scholar
• Marcelin A, Cohen-Codar I, King M, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2005;49:1720–1726.
   PubMed Web of Science ®Google Scholar
• Vora S, Marcelin A, Gunthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS. 2006;20:35–40.
   PubMed Web of Science ®Google Scholar
• Valdez H, Hall D, Kohlbrenner V, et al. Non-response to tipranavir is associated with pretreatment resistance char-acterized by tipranavir phenotype or genotype tipranavir score trials [abstract]. Antivir Ther. 2005;10(suppl):1.
   PubMed Web of Science ®Google Scholar